CORRESPONDENCE

Azithromycin and severe asthma

Brusselle et al\(^1\) performed an interesting academic-based randomised controlled trial Azithromycin for Prevention of Exacerbations in Severe Asthma (AZISAST) of azithromycin 250 mgm taken thrice weekly versus placebo as add-on therapy for 26 weeks in non-smoking patients with severe asthma, defined as Global Initiative for Asthma (GINA) steps 4–5, taking high dose inhaled corticosteroids/long-acting bronchodilators and with at least two severe exacerbations within 6 months of study entry. In the half of subjects with lower blood eosinophil counts (≤200/μl) they detected a significant effect on the primary endpoint (severe exacerbations and/or lower respiratory tract illnesses requiring antibiotics) and also on asthma quality of life (AQL). These results lend additional empirical evidence to support my clinical experience that a significant subgroup of patients with uncontrolled severe asthma will experience important clinical benefits from azithromycin, and that this benefit appears to be ‘all-or-none’\(^2\). My most recent primary care-based trial confirmed this ‘all-or-none’ response pattern and also found that response persisted long after the azithromycin treatment was completed.\(^3\) The primary care severe asthma subjects differed from the AZISAST subjects by including smokers and having worse AQL at randomisation (AQL 4.12 v 5.35 in AZISAST). Many of these primary care responders identified themselves correctly as good candidates for azithromycin.\(^4\)

A pilot trial provided preliminary data that Chlamydia pneumoniae IgA, but not IgG, might be a predictor of treatment response and this needs to be studied further as another possible relevant biomarker.\(^5\) I believe that AZISAST brings us closer to the time when we will understand the mechanisms underlying the azithromycin-asthma response and be able to categorise candidates for treatment, but I do not think that we are there yet.

David L Hahn

Correspondence to Professor David L Hahn, Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, 1100 Delaplaine Court, Madison, WI 53715, USA; dlhahn@wisc.edu

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

To cite Hahn DL. Thorax 2013;68:387.

REFERENCES


http://dx.doi.org/10.1136/thoraxjnl-2012-202698

doi:10.1136/thoraxjnl-2013-203256
Azithromycin and severe asthma

David L Hahn

Thorax 2013 68: 387 originally published online February 7, 2013
doi: 10.1136/thoraxjnl-2013-203256

Updated information and services can be found at:
http://thorax.bmj.com/content/68/4/387.2

These include:

References
This article cites 4 articles, 1 of which you can access for free at:
http://thorax.bmj.com/content/68/4/387.2#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/